ClinicalTrials.gg
Active, not recruitingNCT05354063Updated May 24, 2023

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.

A Phase 1 interventional study of 20 μg dose of SYS6006 and 30 μg dose of SYS6006 in SARS-CoV-2, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Active, not recruiting at 2 sites in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation clinical trial to evaluate the safety and preliminary immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese healthy adults aged 60 years and over.

02

Conditions studied

  • SARS-CoV-2
03

In context

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 60 years or older;
  2. Axillary body temperature is less than 37.3 degree centigrade on the day of enrollment;
  3. Based on the medical history and relevant physical examination and laboratory examination results (normal or abnormal but no clinical significance), the investigator clinically determined that the patient was in good health;
  4. Has independent judgment, and participate voluntarily and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Has a history of SARS-CoV or SARS-CoV-2 infection, or close contact with SARS-CoV-2 infected persons (nucleic acid test positive) or living abroad within 30 days before screening;
  2. Positive SARS-CoV-2 antibody test;
  3. Previous history of allergy to acetaminophen or vaccination(eg, acute allergic reaction, urticaria, dyspnea, angioneurotic edema, or abdominal pain);
  4. Has a history of SARS-CoV-2 vaccination, or have received other inactivated or recombinant vaccines within 7 days, or received within 14 days,before the first dose;
  5. Has a medical history or family history of epilepsy, convulsions, neurological diseases and psychiatric diseases;
  6. Is contraindicative for intramuscular injection, such as having been diagnosed with thrombocytopenia, any coagulation disorder, or receiving anticoagulant therapy;
  7. Has known or suspected severe diseases by the judgement of investigators, including but not limited to: respiratory diseases (lung failure, etc.), liver and kidney diseases, cardiovascular diseases (heart failure, severe hypertension, etc.), malignant tumors, infections or allergic skin diseases, infection, or during the acute infection or chronic disease activity period (within 3 days before vaccination).
  8. Has chronic diseases which at the discretion of investigator are inappropriate for participation(such as Down 's syndrome, sickle cell anemia or neurological disorders, Guillain-Barre syndrome, etc., not including stable diabetes mellitus/hypertension);
  9. Known immunological impairment or dysfunction diagnosed by the hospital before enrollment, or functional asplenia or splenectomy due to any condition;
  10. For women of : positive pregnancy test, being in pregnancy or breastfeeding, or have a pregnancy plan within one year;male: their spouse of childbearing age has plans to become pregnant within 1 year;
  11. Is participating in other clinical trials or plan to participate in other clinical trials during the study period;
  12. Has received immune enhancement or therapy within 3 months before the first dose of vaccine (continuous oral or instillation for more than 14 days); or received whole blood, plasma and immunoglobulin therapy within one month;
  13. Is unlikely to adhere to the study procedures or keep appointments at the discretion of the investigators;or plan to permanently relocate before the end of study; or plan to leave the resident location for a long time at the scheduled visit; or has any other conditions that are inappropriate for participation for this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Vaccine group 1

    20μg dose of SYS6006 vaccine IM, on day 0 and day 21.

    Biological: 20 μg dose of SYS6006

  • Experimental
    Vaccine group 2

    30μg dose of SYS6006 vaccine IM, on day 0 and day 21.

    Biological: 30 μg dose of SYS6006

  • Placebo comparator
    Placebo

    placebo IM, on day 0 and day 21 .

    Drug: Placebo

Interventions

  • Biological20 μg dose of SYS6006

    20 μg dose of SYS6006 vaccine IM on day 0 and day 21.

  • Biological30 μg dose of SYS6006

    30 μg dose of SYS6006 vaccine IM on day 0 and day 21.

  • DrugPlacebo

    Placebo IM on day 0 and day 21.

06

What researchers measure

Primary outcomes

  1. adverse events, including solicited and unsolicited events

    Time frame: From the first dose through 30 days following the second dose.

  2. adverse events associated with the study intervention

    Time frame: From the first dose through 30 days following the second dose.

Secondary outcomes

  1. Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of anti-SARS-CoV-2 antibody (specific IgG antibody and neutralizing antibody )

    Time frame: 14 days after the first dose; 7 days, 14 days, 30 days, 90 days, 180 days and 360 days after the second dose

  2. Serious adverse events (SAE)

    Time frame: from the first dose through 12 months after the second dose.

  3. Adverse events of special interest (AESI)

    Time frame: from the first dose through 12 months after the second dose.

  4. Laboratory test related adverse events

    Time frame: 4 days following each dose.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Sep 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2022
First posted
Apr 29, 2022
StartActual
Jun 1, 2022
Primary completionActual
Sep 5, 2022
CompletionEst.
Oct 1, 2023
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05354063
Responsible party
Sponsor
First posted
Apr 29, 2022
Start date
Jun 1, 2022
Primary completion
Sep 5, 2022
Completion
Oct 1, 2023 (estimated)
Last update
May 24, 2023

Study contacts

Lanjuan Li
principal investigator · Shulan (Hangzhou) Hospital
Guiling Chen
principal investigator · Shulan (Hangzhou) Hospital
Xiang Lu
principal investigator · Sir Run Run Hosipital Nanjing Medical University
Yuwen Su
principal investigator · Sir Run Run Hosipital Nanjing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion